NCT06670963View on ClinicalTrials.gov

Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 1, 2027

Conditions
AnemiaSepsisSeptic Shock
Interventions
DRUG

Iron

Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)

DRUG

EPO

Epoetin alfa 50 units/kg IV 3 times weekly

DRUG

0.9 % NaCl

Volume of 0.9% NaCl identical as volume of medications used in experimental arm

Trial Locations (1)

40-752

RECRUITING

Uniwersyteckie Centrum Kliniczne im. prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice

All Listed Sponsors
lead

Piotr Czempik

OTHER